Kingsoft Cloud Holdings Limited vs Eli Lilly And Co — how do they compare? Kingsoft Cloud Holdings Limited trades at $10.19 (market cap $3.01B), while Eli Lilly And Co trades at $1,165.46 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 338.9× Kingsoft Cloud Holdings Limited's market cap, and Eli Lilly And Co pays a 0.6% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| KC | LLY | |
|---|---|---|
Market Cap | $3.01B | $1.02T |
Sector | Technology | Health |
52-Week High | $18.21 | $1.24K |
52-Week Low | $8.58 | $625.65 |
Enterprise Value | $3.32B | $1.06T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $10.04, up 5.24% today, showing strong momentum despite a bearish technical signal. The company reported Q1 2026 revenue growth of 37% year-over-year, driven by AI cloud demand, though profitability remains challenged with a -9.39% net margin. Analyst sentiment is positive with 70% buy ratings, citing potential from AI expansion and trade easing between the U.S. and China.
KC presents a growth opportunity in cloud and AI services with strong revenue acceleration, but investors face risks from persistent losses, high capital expenditure, and competitive pressures. The stock's outlook hinges on margin improvement from AI investments and sustained demand, making it suitable for growth-oriented investors tolerant of near-term volatility.
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →